In This Article:
Haemonetics Corporation HAE recently entered into a definitive agreement with GVS, S.p.A ("GVS") to sell its whole blood assets. Haemonetics intends to use the proceeds from this transaction for general corporate purposes and additional investments in growth initiatives.
The transaction comprises a total cash consideration of up to $67.1 million, which includes $44.6 million in upfront and up to $22.5 million in contingent earn-outs over the next four years.
HAE’s Likely Stock Trend Following the News
Subsequent to the news, the share price of HAE remained unchanged at $85.26 in Tuesday’s after-market trading.
Haemonetics is continuously focusing on portfolio evolution to enhance leadership in commercial and non-commercial plasma and expand its presence in high-growth hospital markets through various sell-offs. The latest transaction is followed by Haemonetics' agreement in 2020 to sell its Fajardo, Puerto Rico manufacturing operations to GVS and enter a long-term supply and development agreement granting GVS exclusive rights to manufacture and supply the proprietary blood filters produced at the Fajardo facility for Haemonetics. The latest agreement with GVS should enable a smooth transition for Haemonetics' whole blood customers worldwide while supporting the company's goals. Accordingly, we expect the market sentiment to turn in favor of HAE stock in the upcoming days.
Haemonetics currently has a market capitalization of $4.39 billion. The company’s earnings surpassed estimates in three of the trailing four quarters and missed in one, delivering an average earnings surprise of 2.82%.
More on HAE’s Sell-Off Agreement
Under the terms of the agreement, GVS will acquire Haemonetics' complete portfolio of proprietary whole blood collection, processing and filtration solutions. GVS will also acquire Haemonetics' manufacturing facility in Covina, CA, and related equipment and assets at its manufacturing facility in Tijuana, Mexico.
Following the transaction, Haemonetics' Blood Center business will continue to manufacture and provide its full line of apheresis solutions for automated blood collection. These include devices and disposable kits that support a variety of apheresis collections, including platelets, plasma and red cells, and ensure efficient blood center operations.
The transaction is expected to be closed in the first quarter of calendar 2025, subject to the satisfaction of customary closing conditions.
Industry Prospects
Per a Grand View Research report, the global blood processing devices and consumables market is valued at $51.6 billion in 2024 and is anticipated to grow at a compound annual rate of 7.1% from 2025 to 2030. This growth can be attributed to the rising prevalence of infectious diseases necessitating increased blood transfusions and surgical interventions, while an aging population increases the demand for medical processes requiring blood. In addition, technological advancements improve device performance, safety and accuracy, thereby driving market growth.